Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8991726 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL3923672 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL17473729 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL12962519 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL10028312 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL5689239 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL16518819 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL5825056 | 1.00 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| Hydrochloric Acid SCHEMBL8916611 | 0.98 | P2RX4 (0.54) | P2RX4ALDH1A1SERPINE1EPHX1LMNA | |
| SCHEMBL16158123 | 0.87 | P2RX4 (0.55) | P2RX4ALDH1A1SERPINE1EPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12635710-B2 | Methods of using formaldehyde-free antimicrobial compositions in animal by-product compositions | EASTMAN CHEMICAL COMPANY (US) | 2026-05-26 | — | — | US | claimed |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| CN-115297858-B | Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using the same | 赛特瑞恩股份有限公司 | 2024-08-13 | — | — | CN | claimed |
| US-20240215608-A1 | METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONS | EASTMAN CHEMICAL COMPANY (US) | 2024-07-04 | — | — | US | claimed |
| US-20240074436-A1 | ANTIMICROBIAL COMPOSITION FOR ANIMAL FEED | TAMINCO BV (BE) | 2024-03-07 | — | — | US | claimed |
| EP-4319559-A1 | METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONS | Eastman Chemical Company (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| US-5854215-A | Modulators of β-amyloid peptide aggregation | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-12-29 | — | — | US | claimed |
| EP-0885191-A1 | RESOLUTION OF THREO-METHYLPHENIDATE | MEDEVA EUROPE LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032851-A1 | RESOLUTION OF THREO-METHYLPHENIDATE | MEDEVA EUROPE LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
| EP-0420120-B1 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0420120-A2 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-04-03 | — | — | EP | claimed |
| US-4072698-A | OPTICALLY ACTIVE ACIDS WITH KETONE OR ALDEHYDE CATALYST | THE UPJOHN COMPANY (US) | 1978-02-07 | — | — | US | claimed |
| US-3996359-A | ANTIINFLAMMATORY | AB BOFORS (SW) | 1976-12-07 | — | — | US | claimed |
| US-3992534-A | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods | AB BOFORS (SW) | 1976-11-16 | — | — | US | claimed |
| US-3983233-A | ANTIINFLAMMATORY | AB BOFORS (SW) | 1976-09-28 | — | — | US | claimed |
| US-3980700-A | Prostaglandin intermediates and optically active isomers thereof | G. D. SEARLE & CO. (US) | 1976-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | P2RX4 4626/4885ALDH1A1 440/4885SERPINE1 4300/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | P2RX4 4663/4885ALDH1A1 1161/4885SERPINE1 2191/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | P2RX4 4556/4885ALDH1A1 1151/4885SERPINE1 2261/4885 |
| US-12635710-B2 | Methods of using formaldehyde-free antimicrobial compositions in animal by-product compositions | FABP2, FABP1, VIP | P2RX4 4175/4885ALDH1A1 1928/4885SERPINE1 3459/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | P2RX4 4743/4885ALDH1A1 2659/4885SERPINE1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.